SeekingAlpha · Jan 30, 2026
OP
NASDAQ · OPTN
OptiNose, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$9.60
Up+$0.00 (+0.00%)
Updated Sep 17, 2026, 5:10 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 97.22M
- P/E ratio
- -3.75
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 811.06K
- Avg. volume
- 117.68K
Price performance
OPTN price history
1M range · 0 trading sessions · Daily adjusted prices
OPTN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest OPTN news
The latest Smart Investors Daily articles mentioning OPTN.
Stock researchCompany · Overview
OPTN research
Overview
Company profile and research snapshot.
Company profile
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $4.50
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2025 | HC Wainwright & Co. | Neutral | — |
| Mar 21, 2025 | HC Wainwright & Co. | Neutral | — |
| Mar 21, 2025 | Piper Sandler | Neutral | — |
| Mar 20, 2025 | Lake Street | Hold | — |
| Jan 16, 2025 | Lake Street | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · May 21, 2025
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
Paratek Pharmaceuticals has completed the acquisition of Optinose, expanding its portfolio of specialty therapies. The transaction was financed with capital from Paratek, B-FLEXION Life Sciences, and Novo Holdings, as well as debt financing from Oaktree Capital Management.
GlobeNewswire Inc. · Mar 20, 2025
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
Optinose has announced the cancellation of its earnings conference call due to the company's acquisition by Paratek Pharmaceuticals, subject to shareholder and other closing conditions.
Benzinga · Mar 20, 2025
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
Paratek Pharmaceuticals announced it will acquire Optinose, including its approved product XHANCE, to expand its commercial portfolio and strengthen its position as a multi-product company focused on innovative specialty therapies.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
